Community Trust & Investment Co. Has $25.36 Million Stake in CVS Health Corporation $CVS

Community Trust & Investment Co. lowered its position in shares of CVS Health Corporation (NYSE:CVS) by 2.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 245,183 shares of the pharmacy operator’s stock after selling 6,865 shares during the period. CVS Health accounts for approximately 1.3% of Community Trust & Investment Co.’s investment portfolio, making the stock its 22nd biggest holding. Community Trust & Investment Co.’s holdings in CVS Health were worth $25,364,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd grew its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new stake in CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC increased its holdings in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $28,000. 80.66% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CVS. Robert W. Baird set a $107.00 price target on CVS Health in a research note on Thursday. HSBC reaffirmed a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Argus increased their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Sanford C. Bernstein raised their price target on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Mizuho boosted their price target on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $106.46.

CVS Health Stock Down 0.6%

Shares of CVS opened at $95.61 on Friday. The firm has a 50 day simple moving average of $102.26 and a two-hundred day simple moving average of $87.74. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a one year low of $63.30 and a one year high of $110.68. The company has a market cap of $122.28 billion, a P/E ratio of 25.29, a P/E/G ratio of 0.87 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the company posted $1.81 EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Research analysts forecast that CVS Health Corporation will post 8.03 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Thursday, July 23rd. CVS Health’s payout ratio is currently 70.37%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported second-quarter adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. Management raised its 2026 adjusted EPS outlook to $7.90–$8.10, supported by improving performance at Aetna and strength in the retail business. CVS Health earnings and GLP-1 partnership article
• Positive Sentiment: The company expanded its collaboration with Eli Lilly on GLP-1 weight-management treatments. The initiative could help CVS combine its pharmacy, insurance and care-delivery assets to capture a larger role in the growing obesity-treatment market. CVS GLP-1 strategy article
• Positive Sentiment: Analysts have modestly increased their fair-value estimate for CVS from $111.92 to $114.88, reflecting more constructive views following the earnings results, although execution and policy risks remain. CVS fair value estimate article
• Neutral Sentiment: Healthcare was among the sectors receiving defensive ETF inflows, which may provide some broader investor support for CVS, but the flows were concentrated largely in broad-market funds, Treasuries and gold rather than being a company-specific catalyst. Weekly ETF flows article
• Negative Sentiment: Executives warned that Caremark pharmacy-benefit-management membership could decline in 2026 and that changes involving the 340B drug-pricing program may remain a headwind into 2027. These comments overshadowed the earnings beat and guidance increase by raising concerns about future revenue and profit growth. CVS earnings call risks article

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,372,000 shares of company stock worth $317,473,598 over the last three months. 0.85% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.